About PDS Biotechnology Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.pdsbiotech.com
Frequently Asked Questions
What is the 52-week range for PDSB?
The 52-week high is $1.55 and the 52-week low is $0.1952.
What is the P/E ratio for PDSB?
The P/E ratio data is currently unavailable.
What is the dividend yield for PDSB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -346.03%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.55.
Analyst Recommendation Trends
Wall Street analyst consensus for PDSB over the last few months:
Latest PDSB News
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication
PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patientsCompany continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for
PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny
The latest update cuts the fair value price target for PDS Biotechnology from US$5.75 to US$4.75, signaling a more conservative valuation anchor for the stock. Analysts link this change to a mix of optimism around the refocused emphasis on PDS0301 and caution about funding needs, execution risks, and the structure of the Nant led financing. As you read on, you will see how these moving pieces shape the evolving story around PDS Biotechnology and what to watch next. Stay updated as the Fair...
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.
What's going on in today's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Most active stocks in Wednesday's session
Curious about the most active stocks on Wednesday? Find out which stocks are dominating the market action!
Keep an eye on the top gainers and losers in Wednesday's session.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares increased by
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Tuesday's session: most active stocks
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today.
Unusual volume stocks are being observed in Tuesday's session.
Let's have a look at the stocks with an unusual volume in today's session.
Keep an eye on the top gainers and losers in Tuesday's session.
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
PDS Biotech Stock Surges Tuesday: What's Driving the Action?
Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing agreement.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares increased by
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1 earnings
IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet
PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.
What's going on in today's after hours session
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction. The round was led by
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved upwards
The trading volume of these stocks is deviating from the norm in today's session.
Volume analysis on 2026-09-09: stocks with an unusual volume in today's session.
Top movers analysis one hour before the close of the markets on 2026-09-08: top gainers and losers in today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Curious about the most active stocks on Tuesday?
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Top movers analysis in the middle of the day on 2026-09-08: top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
There are notable gap-ups and gap-downs in today's session.
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $5
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $7 to $5.
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Dr. Soon-Shiong will Join PDS Biotech’s Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (“PIPE”) transacti
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August
U.S. stocks fell Tuesday, led by a 450-point Dow drop; health care slid while energy rose. NFIB optimism weakened, oil and copper gained.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-01-12 | BEDU-ADDO FRANK | +548,782 | - | - |
| 2026-01-12 | CONN GREGORY | +150,000 | - | - |
| 2026-01-12 | Shepard Kirk V. | +300,000 | - | - |
| 2026-01-12 | Brown Spencer D. | +300,000 | - | - |
| 2026-01-12 | Toutain Stephan | +300,000 | - | - |
| 2026-01-12 | Freitag Gregory Gene | +54,876 | - | - |
| 2026-01-12 | Iliev Ilian | +54,876 | - | - |
| 2026-01-12 | Ali-Jackson Kamil | +54,876 | - | - |
| 2026-01-12 | Boesgaard Lars | +300,000 | - | - |
| 2026-01-12 | Glover Stephen C. | +54,876 | - | - |
| 2026-01-12 | BRAWLEY OTIS W | +54,876 | - | - |